List of Excipients in Branded Drug CYPROHEPTADINE

Generic Drugs Containing CYPROHEPTADINE

Company	Ingredient	NDC	Excipient
Pharmaceutical Associates Inc	cyproheptadine	0121-0788	ALCOHOL
Pharmaceutical Associates Inc	cyproheptadine	0121-0788	CITRIC ACID MONOHYDRATE
Pharmaceutical Associates Inc	cyproheptadine	0121-0788	D&C YELLOW NO. 10
Pharmaceutical Associates Inc	cyproheptadine	0121-0788	SODIUM BENZOATE
Pharmaceutical Associates Inc	cyproheptadine	0121-0788	SODIUM CITRATE
Pharmaceutical Associates Inc	cyproheptadine	0121-0788	SUCROSE

What are the Most Frequently-Used Excipients in CYPROHEPTADINE?

# Of NDCs	Excipient
2	ALCOHOL
1	ANHYDROUS CITRIC ACID
1	BUTYLATED HYDROXYANISOLE
1	CITRIC ACID MONOHYDRATE
2	D&C YELLOW NO. 10
1	PEPPERMINT

# Cyproheptadine Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Cyproheptadine is a mature, low-cost generic antihistamine and serotonin antagonist with limited active-ingredient exclusivity. Commercial value is concentrated in differentiated dosage forms, pediatric usability, taste masking, preservative systems, sugar-free liquids, orally disintegrating products, and regional licensing. The strongest near-term opportunity is a stable, palatable pediatric formulation that improves dose measurement and adherence without creating a complex regulatory pathway.

What is the commercial status of cyproheptadine?

Cyproheptadine hydrochloride is a first-generation H1 antihistamine with antiserotonergic and anticholinergic activity. In the United States, conventional products include 4 mg tablets and oral solution or syrup containing 2 mg per 5 mL. The drug is used for allergic conditions and is also prescribed off label for appetite stimulation and selected weight-gain applications. [1][2]

Commercial attribute	Cyproheptadine status
Active ingredient	Cyproheptadine hydrochloride
Common tablet strength	4 mg
Common liquid strength	2 mg/5 mL
Drug category	First-generation antihistamine
Regulatory class	Small-molecule prescription generic
Reference product	Periactin
NCE exclusivity	Expired
Generic competition	Established
Biosimilar exposure	None
Primary commercial opportunity	Formulation and delivery differentiation
Key patient groups	Children, adolescents, patients requiring liquid dosing
Main formulation risks	Taste, sedation-related adherence, preservative tolerance, dosing errors

The reference product Periactin is an established product rather than a current exclusivity platform. Generic competition has materially reduced active-ingredient pricing. The commercial case therefore depends on product attributes that pharmacies, caregivers, clinicians, and regional distributors can recognize.

When did cyproheptadine lose exclusivity?

Cyproheptadine lost meaningful compound and new-drug exclusivity decades ago. It is now a conventional generic drug with no biosimilar pathway and no practical opportunity to obtain NCE exclusivity for the active ingredient.

A new cyproheptadine product could qualify for limited regulatory exclusivity only if it satisfies a separate approval pathway, such as a new clinical investigation supporting a 505(b)(2) application. That possibility is distinct from patent protection and requires clinical evidence tied to the proposed change. A reformulated product should not be expected to receive exclusivity merely because it uses a new flavor, sweetener, preservative, or dosage device.

What patents protect cyproheptadine products?

The core cyproheptadine molecule is not commercially protected by an active United States compound patent. Current patent exposure would primarily arise from a later-filed patent covering a specific formulation, delivery system, manufacturing process, or method of use.

Patent category	Current commercial relevance
Core compound patent	No meaningful remaining protection
Tablet composition	Potentially relevant only if a specific later formulation patent remains enforceable
Oral solution composition	Potentially relevant for preservative, pH, taste-masking, or stability claims
Orally disintegrating tablet	Possible formulation or process protection
Extended-release delivery	Possible but commercially unproven for this drug
Method of use	Possible for a narrowly claimed approved indication
Manufacturing process	Relevant if the process is difficult to design around
Device or dosing system	Relevant for combination products or proprietary dispensers

The FDA Orange Book should be checked for any listed patents attached to the proposed reference product and strength before filing. For a mature cyproheptadine product, the larger risk is usually freedom to operate around a later formulation patent rather than a listed compound patent. [3]

What FDA regulatory pathways apply to cyproheptadine reformulations?

A conventional tablet or oral solution that matches an approved reference product may be eligible for an abbreviated new drug application under section 505(j), subject to bioequivalence and inactive-ingredient requirements. A materially different dosage form, release profile, route, or clinical use may require a 505(b)(2) application.

ANDA pathway

An ANDA is most practical when the proposed product:

• Uses the same active ingredient and strength as the reference product.
• Uses the same dosage form.
• Demonstrates bioequivalence.
• Uses inactive ingredients that are acceptable for the intended route and population.
• Does not rely on a new clinical efficacy claim.

A liquid product with a new flavor or sweetener can often remain within an ANDA strategy if the formulation does not create a material safety, efficacy, or bioequivalence issue. Pediatric excipients require particular scrutiny because the acceptable exposure profile can differ from adult products. [4]

505(b)(2) pathway

A 505(b)(2) strategy may apply to:

• Orally disintegrating tablets.
• Modified-release products.
• New delivery systems.
• New routes of administration.
• New strengths not supported by an existing product.
• Products relying on clinical data for a distinct therapeutic use.

A new appetite-stimulation claim would carry substantially greater clinical and regulatory risk than a reformulated antihistamine. The strongest 505(b)(2) opportunities are likely to involve administration and adherence rather than a broad new indication.

Which excipients create the strongest commercial opportunities?

The highest-value excipient strategy is patient-specific. Cyproheptadine is sedating and bitter, and many users are children. Excipients should therefore improve palatability, dose accuracy, physical stability, and tolerability without increasing gastrointestinal burden or preservative exposure.

Pediatric oral solution

A pediatric liquid is the most direct commercial platform. Key excipient categories include:

Excipient function	Candidate strategy	Commercial purpose
Sweetening	Sucralose, acesulfame potassium, sucrose, polyols	Reduce bitterness and improve acceptance
Flavoring	Fruit, berry, bubble-gum, or neutral flavor systems	Improve repeated dosing
Viscosity control	Glycerin, sorbitol, hydroxyethylcellulose, xanthan gum	Improve mouthfeel and reduce dosing splash
Buffering	Citrate or phosphate systems	Control pH and stability
Preservation	Benzoate or sorbate systems where justified	Protect multidose aqueous product
Solubilization	Appropriate co-solvents or surfactants	Maintain clarity and dose uniformity
Osmolality control	Polyols or compatible salts	Reduce irritation and improve palatability
Chelation	EDTA where justified	Reduce metal-catalyzed degradation

The preferred commercial design is likely a low-viscosity, alcohol-free, sugar-free solution with a robust flavor system and a calibrated oral syringe. Sugar-free positioning is important for children with diabetes, dental-risk concerns, and institutional use. A product with sucrose may have lower formulation complexity but less differentiation.

Sorbitol and glycerin can improve mouthfeel but may cause gastrointestinal effects at higher exposure. A formulation should avoid excessive polyol loading, particularly when pediatric doses are repeated. Preservatives should be selected using preservative-effectiveness testing and should be justified against the intended age range.

Taste-masked suspension

A suspension can provide greater flexibility for taste masking and may reduce the need for high levels of dissolved flavor modifiers. It also introduces sedimentation, redispersibility, dose uniformity, and microbial-control risks.

A suspension platform may use:

• Wetting agents.
• Suspending polymers.
• Flocculation-control systems.
• Structured vehicles.
• Flavor and sweetener combinations.
• A labeled shaking instruction.

This approach is commercially attractive if the active ingredient has poor aqueous solubility or if the bitterness of a solution is difficult to suppress. The product must demonstrate dose uniformity throughout the container life, including after storage and repeated opening.

Orally disintegrating tablet

An orally disintegrating tablet could target children, adolescents, and adults who have difficulty swallowing conventional tablets. Excipients may include mannitol, microcrystalline cellulose, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, and flavoring agents.

Mannitol can provide a cooling mouthfeel and rapid dissolution. Crospovidone and related superdisintegrants can support short disintegration times. The main technical problem is bitterness during oral disintegration. A taste-masked granule, coated particle, ion-exchange complex, or lipid-based barrier may be required.

An ODT is more likely to require 505(b)(2) treatment if the dosage form differs materially from approved products. It may also create a formulation patent opportunity, but the claims must be narrow enough to distinguish ordinary ODT practice and broad enough to resist design-around.

Sprinkle or multiparticulate formulation

A sprinkle product could be administered with soft food or a beverage. This platform is relevant to children and patients with swallowing difficulty, but it creates additional requirements for:

• Particle-size control.
• Content uniformity.
• Food compatibility.
• Stability after opening.
• Taste masking.
• Dose recovery from the administration vehicle.

Multiparticulates can support taste masking and potentially modified release. A simple immediate-release sprinkle product is more commercially credible than an extended-release version because cyproheptadine’s sedative and anticholinergic effects complicate exposure management.

What formulations are most attractive for licensing?

The most licensable concepts are products that combine a clear patient benefit with manageable development costs.

Opportunity	Development complexity	Differentiation	Licensing potential
Sugar-free pediatric solution	Low to moderate	Moderate	High
Alcohol-free flavored syrup	Low to moderate	Moderate	High
Taste-masked ODT	Moderate	High	High
Sprinkle granules	Moderate to high	High	Moderate
Extended-release tablet	High	High	Moderate
Compounded formulation platform	Low	Low	Limited
Prefilled oral syringe product	Moderate	Moderate	Moderate

A drug-delivery company could license a taste-masking technology to a generic manufacturer. A regional pharmaceutical company could license rights for a pediatric liquid, especially in markets where cyproheptadine is widely used but branded pediatric products are limited.

No major active originator licensing structure is central to the current cyproheptadine market. Commercial negotiations are more likely to involve formulation developers, generic manufacturers, contract development and manufacturing organizations, and regional distributors.

What generic entry risks exist for a new cyproheptadine formulation?

Generic entry risk is high for a conventional 4 mg tablet and moderate to high for a standard 2 mg/5 mL liquid. A differentiated product can reduce direct substitution risk only if it has one or more of the following:

• A pediatric-friendly flavor with documented acceptance.
• A clear sugar-free or preservative-reduced profile.
• A calibrated dosing device.
• A stable formulation with a longer in-use period.
• A novel dosage form.
• Supply reliability in a market with limited liquid competition.
• Packaging that reduces dosing errors.

A generic manufacturer can usually copy the therapeutic concept while changing flavor, sweetener, polymer, or packaging. Patent claims should therefore cover the technically essential combination rather than a single common excipient.

How strong is the patent estate for cyproheptadine?

The overall patent estate is weak at the active-ingredient level and potentially moderate for a well-supported formulation platform.

Patent-strength assessment

Patent area	Expected strength
Compound	Very low
Standard tablet	Low
Basic flavored liquid	Low to moderate
Specific preservative and pH system	Moderate if supported by stability data
Taste-masked ODT	Moderate to strong if technically distinctive
Device-linked dosing system	Moderate
Extended-release formulation	Moderate, with high development risk
Manufacturing process	Moderate if process parameters produce unexpected quality benefits
Broad appetite-stimulation method	Low to moderate because of prior art and clinical complexity

The most defensible claims would likely link excipient ratios, particle engineering, dissolution behavior, taste-masking performance, stability, and dose uniformity. A claim that merely lists cyproheptadine with a conventional sweetener is unlikely to provide durable protection.

What patent litigation and Paragraph IV challenges affect cyproheptadine?

Cyproheptadine is not associated with a major current patent-litigation campaign comparable to recently approved specialty drugs. Paragraph IV risk is correspondingly limited for legacy products without meaningful Orange Book-listed patents.

A new formulation could generate Paragraph IV activity if it receives a 505(b)(2) approval with listed patents. The likely challengers would be established generic manufacturers that already sell cyproheptadine tablets or liquids. The most probable challenge would target:

• Obviousness of the excipient combination.
• Lack of written description or enablement.
• Inherency of claimed dissolution or stability results.
• Design-around availability.
• Adequacy of the method-of-use claim.

A patent owner should expect a short commercial life if protection rests only on a flavor, ordinary sweetener, or standard preservative. Litigation value increases when the formulation solves a measurable technical problem, such as sustained taste masking through the full dose period or improved stability under stressed storage.

What is the FDA and Orange Book status of cyproheptadine?

Cyproheptadine is an established FDA-regulated prescription product with generic availability. FDA labeling identifies cyproheptadine hydrochloride tablets and oral liquid products for antihistaminic use. [1][2]

The Orange Book is the controlling source for current reference-listed products, therapeutic-equivalence evaluations, patent listings, and exclusivity information. For a mature cyproheptadine product, the expected commercial profile is:

• No remaining NCE exclusivity.
• Multiple generic approvals.
• No biosimilar pathway.
• Limited likelihood of active listed patents on the basic product.
• Potential formulation-specific patent activity for newer products.

Applicants should evaluate the current Orange Book entry at the time of filing because listed patents and reference-product status can change. [3]

How does cyproheptadine compare with competing appetite-stimulation products?

Cyproheptadine competes indirectly with nutritional supplements, megestrol acetate, mirtazapine, corticosteroids, and nonpharmacologic nutrition programs in appetite-related use. It competes directly with other first-generation antihistamines for allergic indications.

Product or category	Main advantage	Main limitation relative to cyproheptadine
Cyproheptadine	Low cost, liquid availability, appetite-related off-label use	Sedation, anticholinergic effects
Megestrol acetate	Stronger appetite positioning in selected populations	More serious safety concerns and narrower use
Mirtazapine	Appetite and sleep effects in selected patients	Different psychiatric risk and indication profile
Cetirizine or loratadine	Less sedation	No comparable appetite-stimulation profile
Nutritional products	No prescription pathway	Variable evidence and adherence
Compounded liquids	Flexible dosing	Variable quality, limited commercial consistency

The formulation opportunity is strongest where cyproheptadine’s low price is preserved while administration problems are reduced.

What manufacturing and intellectual-property barriers matter?

Manufacturing barriers are modest for conventional tablets but increase for taste-masked and pediatric products. Critical controls include:

• Assay and content uniformity at low dose.
• Control of cyproheptadine polymorph or solid-state behavior where relevant.
• Preservation of multidose liquids.
• Flavor stability over shelf life.
• Container-closure compatibility.
• Accurate delivery through oral syringes.
• Uniform redispersion for suspensions.
• Control of residual solvents if coating or taste-masking processes are used.

A proprietary manufacturing process is most valuable when it produces a measurable result that competitors cannot easily reproduce. Examples include reduced bitterness without delayed dissolution, improved liquid stability without high preservative loading, or a robust ODT that remains mechanically strong while disintegrating rapidly.

What is the best commercial strategy for cyproheptadine?

The preferred strategy is a staged pediatric product program:

1. Develop a sugar-free, alcohol-free oral solution at 2 mg/5 mL.
2. Use a low-polyol vehicle with a validated fruit or neutral flavor system.
3. Package the product with an oral syringe and dosing adapter.
4. Generate stability, preservative-effectiveness, palatability, and dose-delivery data.
5. Evaluate ANDA eligibility before pursuing a 505(b)(2) route.
6. Reserve patent filings for technically supported excipient combinations and delivery features.
7. Follow with an ODT or sprinkle product if pediatric-market uptake supports expansion.

This approach limits development risk while creating licensing value for generic manufacturers and regional pharmaceutical companies.

Key Takeaways

• Cyproheptadine has no meaningful remaining compound exclusivity.
• Biosimilar risk is irrelevant because cyproheptadine is a small molecule.
• Conventional tablets and syrups face high generic competition.
• Pediatric liquids offer the clearest commercial opportunity.
• Sugar-free, alcohol-free, palatable formulations can support product differentiation.
• Taste-masked ODTs and sprinkle products offer stronger formulation differentiation but require more development work.
• Basic sweetener or flavor patents would likely be weak.
• Stronger protection would combine excipient composition, stability, dissolution, taste masking, and delivery performance.
• The likely regulatory route is an ANDA for a conventional equivalent product and a 505(b)(2) application for a materially different dosage form.
• The FDA Orange Book should be reviewed before filing to confirm current reference-product, patent, and exclusivity data.

FAQs

Is cyproheptadine still patent protected?

The active ingredient is not meaningfully protected by a live compound patent in the United States. Any current risk would arise from a later formulation, manufacturing, device, or method-of-use patent.

Can a company obtain exclusivity for a new cyproheptadine liquid?

A new liquid does not automatically receive exclusivity. Limited exclusivity may be possible through a 505(b)(2) approval supported by qualifying clinical investigations, but a routine generic reformulation generally will not receive NCE exclusivity.

Which excipient is best for masking cyproheptadine taste?

No single excipient is sufficient in every formulation. A combined system using sweetener, flavor, viscosity control, pH adjustment, and potentially coated or complexed drug particles is more likely to control bitterness across the full dose.

Is a cyproheptadine sugar-free product commercially differentiated?

Yes, particularly in pediatric and institutional markets. Differentiation is strongest when sugar-free status is combined with good palatability, low gastrointestinal burden, accurate dosing, and documented stability.

Can cyproheptadine be developed as an extended-release product?

It can be technically developed, but the commercial and regulatory burden is higher. Exposure control must be balanced against sedation and anticholinergic effects, and the product would likely require substantial formulation and pharmacokinetic work.

References

1. U.S. Food and Drug Administration. (n.d.). Cyproheptadine hydrochloride prescribing information. FDA labeling database.

2. National Library of Medicine. (n.d.). Cyproheptadine hydrochloride tablet and oral solution labeling. DailyMed.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

4. U.S. Food and Drug Administration. (2016). Inactive ingredient database. FDA.